Sygnature Discovery Limited
Max Mirza is a neuroscientist who has worked in biotech, big and midsize pharma for over 25 years. He has run and overseen multiple drug discovery projects from medicinal chemistry through to Phase 2a, working with internal teams, CROs, academics, and investors to progress projects taking a stage-gated decision guided approach.
At the biotech NeuroSearch he was involved in multiple multi-year collaborations with major pharma companies focused on CNS & Pain projects from research to early clinical development.
He co-founded and was CSO of the CNS-focused biotech Saniona, listed on the Stockholm Nasdaq.
At Pfizer, he was part of the external R&D team focused on bolstering the internal pain and neuroscience pipeline and capabilities, working closely with commercial and BD teams, with an emphasis on novel therapeutic modalities.
Prior to joining Sygnature Discovery, Max was at Mundipharma where he was charged with innovating in pain, neuroscience, metabolic disorders, and infectious disease working closely with commercial and reimbursement teams. Max continues to consult for various VCs and investment teams in neuroscience.
This person is not in any offices
Sygnature Discovery Limited
2 followers
Sygnature Discovery are a leading drug discovery CRO with expertise across a range of therapeutic and biological target classes. An expert partner in disciplines including Medicinal and Computational Chemistry, In Vitro and In Vivo Pharmacology, DMPK, supported by informatics.